Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 5Terminated 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 3Sarcoma 2Myeloid 2Lymphoid 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 86Leukemia 50Gastrointestinal Stromal Tumors 41Leukemia, Myeloid, Chronic-Phase 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Blast Crisis 17Philadelphia Chromosome 13Brain Neoplasms 12Sarcoma 10Leukemia, Myeloid, Acute 10Glioblastoma 10Lung Neoplasms 9Leukemia, Myeloid, Accelerated Phase 9Gliosarcoma 9Prostatic Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Glioma 7Oligodendroglioma 6Melanoma 6Leukemia, Myelomonocytic, Chronic 6Dermatofibrosarcoma 6Astrocytoma 6Small Cell Lung Carcinoma 5Recurrence 5Primary Myelofibrosis 5Polycythemia Vera 5Ovarian Neoplasms 5Leukemia, Myeloid 5Central Nervous System Neoplasms 5

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Recurrence × Imatinib Mesylate × Clear all
NCT02081378 2024-03-18

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Novartis

Phase 1 Completed
326 enrolled 1 FDA
MyeloidOther hematologic neoplasm

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00036738 2020-01-29

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Fred Hutchinson Cancer Center

Phase 2 Completed
28 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01172548 2017-05-31

INV555

Novartis

Phase 2 Completed
132 enrolled
GastrointestinalSarcoma

Recurrence, Gastrointestinal Stromal Tumors

NCT00955916 2014-06-27

CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
38 enrolled 8 charts
Other hematologic neoplasm

Blast Crisis, Leukemia, Recurrence

NCT00243191 2012-03-29

Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
18 enrolled 7 charts
Sarcoma

Recurrence, Dermatofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡